annual meeting program - American Society of Clinical Oncology

Monday, June 7, 2010
Brd. 48E Cancer treatment impact on cognitive functioning and quality of life in lung
cancer survivors. (Abstract #9112)
S. Kohli, P. J. Novotny, J. A. Sloan, J. C. Buckner, P. D. Brown, P. Yang
Brd. 48F A phase II clinical study of interleukin-11 mutein to treat patients with
chemotherapy-induced thrombocytopenia. (Abstract #9113)
Y. Jung, S. Ho, S. Yu, S. Wu, Y. Zhang, L. Xu, Y. Dai, Y. Teng, S. Ma, S. Song
Brd. 48G Can the short screening test Vulnerable Elders Survey 13 (VES-13) substitute
for the time-consuming comprehensive geriatric assessment (CGA) to
identify vulnerable/frail elderly breast cancer patients? (Abstract #9114)
S. Monfardini, U. Basso, P. Fiduccia, A. Brunello, Z. Baretta, C. Soldà, E. Lamberti,
F. Bozza, A. Jirillo, C. Falci
Brd. 48H A real-world evaluation of the effectiveness of dalteparin in the prevention of
recurrent venous thromboembolism compared to warfarin in patients with
cancer. (Abstract #9115)
W. R. Simons, Y. Choe, A. Powers, C. McQueen
Brd. 49A A report on the development and validation of first-ever perceptual speech
evaluation tool for head and neck cancer (HNC) patients. (Abstract #9116)
R. C. Dwivedi, S. St. Rose, C. Nutting, P. H. Rhys-Evans, K. J. Harrington, R. Kazi
Brd. 49B Adolescent and young adult use of Internet-based cancer survivorship care
plans. (Abstract #9117)
C. E. Hill-Kayser, C. Vachani, M. K. Hampshire, L. A. Jacobs, J. M. Metz
Brd. 49C Predictors of employment (empl) outcomes in outpatients (pts) with common
solid tumors: A secondary analysis from E2Z02 (ECOG’s SOAPP study).
(Abstract #9118)
A. Tevaarwerk, J. Lee, M. C. Sesto, K. A. Buhr, C. S. Cleeland, J. Manola,
L. I. Wagner, V. T. Chang, M. Fisch
Brd. 49D Enrollment of and toxicity in patients 70 years and older on CTEP/NCIsponsored,
single-agent phase I studies from 1980 to 2005. (Abstract #9119)
S. L. Chow, Y. Lin, N. K. LoConte, R. B. Royds, T. G. Nekrassova, S. P. Ivy,
J. Mauer, G. Wilding, R. Stoller, M. J. Egorin
Brd. 49E A prospective evaluation of symptom change over 4 weeks for outpatients
with common solid tumors: Results from E2Z02 (the SOAPP study).
(Abstract #9120)
M. Fisch, J. Lee, V. T. Chang, L. I. Wagner, D. Cella, L. M. Minasian,
W. J. McCaskill-Stevens, M. Weiss, M. Smith, C. S. Cleeland
Brd. 49F Prechemotherapy hepatitis B virus (HBV) screening in medical oncology
patients: A national survey. (Abstract #9121)
F. L. Day, E. Link, K. Thursky, D. Rischin
Brd. 49G Pregnancy and survival after primary breast carcinoma in young women: A
meta-analysis of healthy mother effect studies. (Abstract #9122)
D. Mauri, A. Valachis, L. Tsali, K. Tsalis, N. P. Polyzos, L. L. Pesce
Brd. 49H Patients’ self-assessment of tolerance and quality of life during docetaxelbased
chemotherapy: Results from a phase III trial in hormone-naive
metastatic prostate cancer patients (GETUG-AFU 15/0403). (Abstract #9123)
F. Joly, G. Gravis, S. Oudard, M. Soulie, B. Esterni, C. Protiere, M. Habibian,
I. Latorzeff, F. Priou, K. Fizazi
Brd. 50A Out-of-pocket (OOP) spending burden for Medicare beneficiaries with
cancer. (Abstract #9124)
X. Ke, F. Hendrick, T. Shaffer, A. J. Davidoff
Brd. 50B Development of the lymphedema symptoms intensity and distress survey
arm. (Abstract #9125)
S. H. Ridner, M. S. Dietrich
Brd. 50D Chemotherapy-induced nausea and vomiting-associated hospital and ER
visits in real-world practice: Palonosetron versus other 5-HT3-RA anti-emetic
regimens. (Abstract #9127)
H. T. Hatoum, S. Lin, D. Buchner, D. Cox
383
MONDAY